Vaccibody AS

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers and infectious diseases with a high unmet medical need. VB10.NEO, its individualized cancer neoantigen vaccines is exclusively licensed to Genentech. Vaccibody’s most advanced program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first in-human study (phase I/IIa), evaluating the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) has been finalized and has published positive 12 months data. Vaccibody has recently started a collaboration with Roche, exploring VB10.16 in combination with CPI atezolizumab (Tecentriq™) in up to 50 patients with advanced or recurrent cervical cancer. First patients have be vaccinated. Further, Vaccibody is exploring vaccines against infectious diseases.